News
Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...
Hosted on MSN2m
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
The company’s Q2 revenue jumped 38% to $15.56 billion, with $5.2 billion from Mounjaro and $3.38 billion from Zepbound.
Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...
NEW YORK (AP) — Stocks are rising on Wall Street Thursday, even as President Donald Trump’s latest tariffs kicked into effect ...
U.S. stocks drifted to a mixed finish on Thursday as President Donald Trump’s tariffs taking effect on dozens of countries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback